These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 32083130)
1. Characterizations of Gene Alterations in Melanoma Patients from Chinese Population. Luo Y; Zhang Z; Liu J; Li L; Xu X; Yao X; Dai Z; Wang X; Yang S; Wu H; Bu J; Wu Y; Xiang T; Li X Biomed Res Int; 2020; 2020():6096814. PubMed ID: 32083130 [TBL] [Abstract][Full Text] [Related]
2. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Si L; Kong Y; Xu X; Flaherty KT; Sheng X; Cui C; Chi Z; Li S; Mao L; Guo J Eur J Cancer; 2012 Jan; 48(1):94-100. PubMed ID: 21788131 [TBL] [Abstract][Full Text] [Related]
4. Distinct sets of genetic alterations in melanoma. Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983 [TBL] [Abstract][Full Text] [Related]
5. Mutational profiling of acral melanomas in Korean populations. Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690 [TBL] [Abstract][Full Text] [Related]
6. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur. Kang X; Zeng Y; Liang J; Li J; Ren D; Chai L; Sun Z; Yu S; Wu X; Han W; Wang W Medicine (Baltimore); 2018 Jan; 97(1):e9509. PubMed ID: 29505523 [TBL] [Abstract][Full Text] [Related]
7. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166 [TBL] [Abstract][Full Text] [Related]
8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
9. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Vízkeleti L; Ecsedi S; Rákosy Z; Orosz A; Lázár V; Emri G; Koroknai V; Kiss T; Ádány R; Balázs M Tumour Biol; 2012 Dec; 33(6):2189-99. PubMed ID: 23001925 [TBL] [Abstract][Full Text] [Related]
10. BRAF mutation status in primary and metastatic melanomas in two regions with differing potential ultraviolet radiation exposure. Massad C; Loya A; Taraif S; Saroufim M; Kibbi AG; Habib R; Novy M; Rauscher B; Oberkanins C; Khalifeh I Clin Exp Dermatol; 2014 Dec; 39(8):932-43. PubMed ID: 25262755 [TBL] [Abstract][Full Text] [Related]
11. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090 [TBL] [Abstract][Full Text] [Related]
12. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Rawson RV; Johansson PA; Hayward NK; Waddell N; Patch AM; Lo S; Pearson JV; Thompson JF; Mann GJ; Scolyer RA; Wilmott JS Lab Invest; 2017 Feb; 97(2):130-145. PubMed ID: 28067894 [TBL] [Abstract][Full Text] [Related]
13. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143 [TBL] [Abstract][Full Text] [Related]
14. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048 [TBL] [Abstract][Full Text] [Related]
16. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057 [TBL] [Abstract][Full Text] [Related]
17. GAB2 amplifications refine molecular classification of melanoma. Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136 [TBL] [Abstract][Full Text] [Related]
18. BRAF V600 mutations and pathological features in Japanese melanoma patients. Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202 [TBL] [Abstract][Full Text] [Related]
19. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals. Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319 [TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in primary melanoma in Taiwan. Sheen YS; Tan KT; Tse KP; Liao YH; Lin MH; Chen JS; Liau JY; Tseng YJ; Lee CH; Hong CH; Liao JB; Chang HT; Chu CY Br J Dermatol; 2020 May; 182(5):1205-1213. PubMed ID: 31408190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]